Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Colon, Gastrointestinal, Rectal
Status:
Open
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Eligible for screening study DCP 001
A221805 is reopened to accrual to the Phase III portion with the implementation of Update 5, effective 02/20/24
A221805, Phase II, is closed to accrual effective March 31, 2023, at 4:30 ET. If interim analysis is positive, Phase III will open to accrual.
A221805-Substudy SI1 is closed to accrual, effective September 15, 2022, at 4:30pm ET.
NCT#04137107